Investigation Plan (PIP): The PIP must be submitted to the European Medicines Agency (EMA) and is assessed to ensure that appropriate studies are planned to generate data in children.

Orphan Drug Designation: This designation is granted by the EMA for medicines intended for the diagnosis, prevention, or treatment of rare diseases affecting fewer than 5 in 10,000 people in the EU.

Documentation

The preparation of a PIP or an application for orphan designation requires diligent documentation aligned with regulatory expectations. Here are the core documents typically required:

For Paediatric Investigation Plans:

• PIP Application: A form detailing the planned clinical studies inclusive of timelines, objectives, endpoints, and methodologies.
• Justification of Waiver: Documents seeking a waiver must outline scientific reasons for not complying with the PIP requirements, supported by robust justifications.
• Strategy for Data Generation: This should include timelines, pharmacokinetics, pharmacodynamics, and dose-finding studies tailored to paediatric patients.

For Orphan Drug Designation:

• Application Form: Consisting of a detailed description of the condition, the unmet medical need, and the proposed therapy.
• Scientific Evidence: Data validating the rarity of the disease and the potential benefits of the proposed orphan medicinal product.
• Market Exclusivity Plan: A proposal outlining how exclusivity will support the viability of the product post-approval.

Review/Approval Flow

Once the appropriate documentation is prepared, it enters the review cycle as follows:

Pediatric Investigation Plan Review:

1. Submission to the EMA: The PIP is submitted to the EMA’s Paediatric Committee (PDCO) for evaluation.
2. Assessment Period: The PDCO reviews the application and provides its opinion, usually within 60 days.
3. Outcome Notification: A positive opinion leads to the obligation to implement the PIP as part of the Marketing Authorization Application (MAA).

Orphan Drug Designation Review:

1. Application Submission: The orphan application is submitted to the EMA.
2. Review by the Committee for Orphan Medicinal Products (COMP): Following the assessment, COMP issues its opinion in a timeframe typically not exceeding 90 days.
3. Granting of Designation: A positive opinion is followed by official designation of the orphan status, leading to potential benefits for future development and marketing.

Common Deficiencies

To increase the probability of success during the review process, it is paramount to avoid typical pitfalls. Common deficiencies that may arise include:

• Insufficient Scientific Justification: Failing to provide adequate scientific rationale for planned paediatric studies, which may lead to a request for additional data or modifications to the PIP.
• Lack of Comprehensive Clinical Data: For orphan applications, inadequately addressing the rare disease characteristics or providing insufficient evidence of the unmet medical need can result in failure to receive designation.
• Inconsistencies in Documentation: Discrepancies between submitted documents during the PIP and orphan designation processes can confuse reviewers and create a perception of lack of diligence.

RA-Specific Decision Points

In navigating the regulatory landscape involving PIPs and orphan designations, there are several critical decision points for Regulatory Affairs (RA) teams to consider:

When to File as Variation vs. New Application

It is essential to determine whether a proposed change in a PIP requires a variation or a new application. This decision hinges on:

• Magnitude of Change: Is the modification minor (e.g., small amendments to study design) or a major change affecting the overall development strategy?
• Impact on Data Generation: Will the variation affect the data generated in relation to the paediatric population?

How to Justify Bridging Data

In scenarios where bridging data from adult studies are employed to support PIP compliance, the following considerations are critical:

• Relevance of Data: Clearly demonstrate how adult data are applicable to the paediatric population.
• Age-Appropriate Justification: Provide a rationale as to why findings from adults translate effectively into conclusions regarding safety and efficacy in children.

Convergence with Other Regulatory Functions

Accessing the full potential of PIPs and orphan drug designations requires robust interaction among various functions in the pharmaceutical company.

• Clinical Affairs: Collaboration with clinical teams is paramount for developing trials that satisfy regulatory expectations while also considering ethical implications in paediatrics.
• Pharmacovigilance: Ongoing safety monitoring and adverse event reporting as required by regulatory requirements yield critical data for periodic updates and approvals.
• Commercial Strategy: Effective market access planning should consider the potential orphan designation benefits and investigate possibilities for expedited pathways.

Practical Tips for RA Teams

To facilitate smoother interactions with regulatory agencies and improve submission success rates, RA teams should adopt best practices:

• Engage Early with EMA: Utilize the EMA’s Scientific Advice procedure to discuss PIP or orphan designations before formal submission.
• Anticipate Questions: Thoroughly prepare responses for likely agency queries based on previous reviews and common deficiencies encountered in related applications.
• Maintain Clear Documentation: Ensure that all documentation is organized, clear, concise, and follows the regulatory format required by EMA and relevant committees.

By adhering to this structured approach, Regulatory Affairs professionals can effectively navigate the complex landscape of paediatric and orphan regulations within the EU framework, ensuring compliance and promoting the successful development of medicines for targeted populations.

For further information on the requirements for Paediatric Investigation Plans and Orphan Designation, refer to the European Medicines Agency’s official guidelines.